Ciprofloxacin monohydrochloride (Synonyms: Bay-09867 monohydrochloride)

Name: Ciprofloxacin monohydrochloride
Brand: MedChemExpress
SKU: HY-B0356A
Rating: 5.0 (29 reviews)

Cat. No.: HY-B0356A Purity: 99.90%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ciprofloxacin (Bay-09867) monohydrochloride is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin monohydrochloride induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin monohydrochloride has anti-proliferative activity and induces apoptosis. Ciprofloxacin monohydrochloride is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity.

For research use only. We do not sell to patients.

Ciprofloxacin monohydrochloride Chemical Structure

CAS No. : 93107-08-5

Size	Price	Stock	Quantity
500 mg	USD 30	In-stock	Estimated Time of Arrival: December 31
1 g	USD 45	In-stock	Estimated Time of Arrival: December 31
5 g	USD 90	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 29 publication(s) in Google Scholar

Other Forms of Ciprofloxacin monohydrochloride:

Ciprofloxacin In-stock
Ciprofloxacin-d₈ hydrochloride hydrate Get quote
Ciprofloxacin-¹³C₃,¹⁵N monohydrochloride Get quote
Ciprofloxacin hydrochloride monohydrate Get quote
Ciprofloxacin lactate Get quote
Ciprofloxacin monohydrochloride (Standard) Get quote

29 Publications Citing Use of MCE Ciprofloxacin monohydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

Topoisomerase Topo I Topo II

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

Quinolone

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	> 128 μM Compound: CFX	Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
A-431	IC₅₀	135 μM Compound: 1	Inhibition of human A431 cell proliferation by MTT assay Inhibition of human A431 cell proliferation by MTT assay	[PMID: 19595598]
A-431	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human A431 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
A549	IC₅₀	> 100 μM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human A549 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]
A549	IC₅₀	> 302 nM Compound: Ciprofloxacin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30660827]
A549	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against human A549 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
A549	IC₅₀	280 μM Compound: 1	Antitumor activity against human A549 cells after 5 days by MTT assay Antitumor activity against human A549 cells after 5 days by MTT assay	[PMID: 19595598]
B-cell	IC₅₀	123 μM Compound: ciprofloxacin	Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs Antiproliferative activity against Theileria parva-induced proliferation of bovine B lymphocyte assessed as inhibition of [3H]thymidine uptake after 48 hrs	[PMID: 19075064]
CAPAN-1	IC₅₀	> 100 μM Compound: Ciprofloxacin	Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Capan1 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
CHO	IC₅₀	> 150 μM Compound: CFX	Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay Cytotoxicity against Chinese hamster CHO cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
CHO	CC₅₀	512 μM Compound: CPFX	Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against CHO cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31525660]
CT26	IC₅₀	0.33 mM Compound: CFX	Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay Antitumor activity against mouse CT26 cells assessed as reduction in cell viability incubated for 4 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	> 128 μM Compound: CFX	Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human EJ cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
EJ	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human EJ cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
EJ	IC₅₀	202 μM Compound: 1	Inhibition of human EJ cell proliferation by MTT assay Inhibition of human EJ cell proliferation by MTT assay	[PMID: 19595598]
HaCaT	IC₅₀	222.1 μM Compound: CP	Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HaCaT cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
HBL-100	IC₅₀	10.28 μM Compound: C; Cip	Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HBL-100 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34319100]
HEK-293T	CC₅₀	> 60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
HeLa	IC₅₀	> 100 μM Compound: Ciprofloxacin	Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay Cytotoxicity against human HeLa cells after 24 hrs by LDH release assay	[PMID: 27018907]
HeLa	IC₅₀	120 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	290 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against HeLa cells after 48 hrs Antiproliferative effect against HeLa cells after 48 hrs	[PMID: 17088489]
HeLa	IC₅₀	800 μM Compound: 1	Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
Hep 3B2	IC₅₀	> 100 μM Compound: Ciprofloxacin	Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human Hep3B cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HEp-2	CC₅₀	> 100 μM Compound: CIP	Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay	[PMID: 21425851]
HEp-2	CC₅₀	> 100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 21443219]
HEp-2	CC₅₀	> 100 μM Compound: CIP	Cytotoxicity against human Hep2 cell line after 72 hrs Cytotoxicity against human Hep2 cell line after 72 hrs	[PMID: 17228862]
HepG2	IC₅₀	> 0.5 mM Compound: CPX, B-H	Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay Cytotoxicity against human HepG2 cells measured after overnight incubation by MTT assay	[PMID: 21855181]
HepG2	CC₅₀	> 100 μM Compound: CIP	Cytotoxicity against human HepG2 cells after 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs	[PMID: 17228862]
HepG2	IC₅₀	> 128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability for 24 hrs by Celltiter-Glo assay	[PMID: 35231579]
HepG2	IC₅₀	> 128 μg/mL Compound: CIP	Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay	[PMID: 27499455]
HepG2	CC₅₀	138.6 μg/mL Compound: CPX	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by ATP bioluminescence assay	[PMID: 30067360]
HepG2	IC₅₀	27 μM Compound: Ciprofloxacin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 7 days by MTT assay	[PMID: 28237557]
HL-60	IC₅₀	> 100 μM Compound: Ciprofloxacin	Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	> 150 μM Compound: CFX	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
HL-60	IC₅₀	> 302 nM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay	[PMID: 30660827]
HL-60	IC₅₀	≥ 100 μM Compound: Ciprofloxacin	Antiproliferative activity against human HL60 cells by MTT assay Antiproliferative activity against human HL60 cells by MTT assay	[PMID: 30660827]
K562	IC₅₀	> 150 μM Compound: 1	Inhibition of human K562 cell proliferation by sulphorodhamine B assay Inhibition of human K562 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
KB	IC₅₀	> 128 μM Compound: CFX	Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human KB cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
KB	IC₅₀	160 μM Compound: 1	Inhibition of human KB cell proliferation by MTT assay Inhibition of human KB cell proliferation by MTT assay	[PMID: 19595598]
L02	IC₅₀	12.23 μM Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L02	IC₅₀	4.05 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells after 72 hrs by CCK-8 assay	[PMID: 35398730]
L1210	IC₅₀	> 100 μM Compound: Ciprofloxacin	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
L1210	IC₅₀	> 150 μM Compound: CFX	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
L1210	IC₅₀	> 150 μM Compound: CFX	Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against mouse L1210 cells assessed as reduction in cell viability by MTT assay	[PMID: 31881454]
L1210	IC₅₀	≥ 100 μM Compound: Ciprofloxacin	Antiproliferative activity against mouse L1210 cells by MTT assay Antiproliferative activity against mouse L1210 cells by MTT assay	[PMID: 30660827]
LoVo	IC₅₀	89 μM Compound: 1	Antitumor activity against human LoVo cells after 5 days by MTT assay Antitumor activity against human LoVo cells after 5 days by MTT assay	[PMID: 19595598]
MC3T3-E1	IC₅₀	120 μM Compound: 1	Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs Inhibition of mouse MC3T3-E1 cell proliferation after 48 to 72 hrs	[PMID: 19595598]
MCF-10A	IC₅₀	> 300 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay Cytotoxicity against human MCF10A cells after 48 hrs by WST1 assay	[PMID: 24513049]
MCF7	IC₅₀	> 100 μM Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
MCF7	IC₅₀	> 128 μM Compound: CFX	Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
MCF7	IC₅₀	199 μM Compound: 1	Inhibition of human MCF7 cell proliferation by MTT assay Inhibition of human MCF7 cell proliferation by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	476 μM Compound: 1	Antitumor activity against human MCF7 cells after 5 days by MTT assay Antitumor activity against human MCF7 cells after 5 days by MTT assay	[PMID: 19595598]
MCF7	CC₅₀	60 μg/mL Compound: Ciprofloxacin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 27720324]
MCF7	IC₅₀	76 μM Compound: 1	Inhibition of human MCF7 cell proliferation after 5 days by MTT assay Inhibition of human MCF7 cell proliferation after 5 days by MTT assay	[PMID: 19595598]
MCF7	IC₅₀	8.85 μM Compound: C; Cip	Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antitumor activity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 34319100]
MG-63	IC₅₀	150 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	160 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs	[PMID: 17088489]
MG-63	IC₅₀	480 μM Compound: 1	Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
MRC5	IC₅₀	53.4 μg/mL Compound: CPF	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31431360]
MT4	CC₅₀	60 μM Compound: Ciprofloxacin	Concentration required to reduce the viability of mock-infected MT-4 cells by 50% Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	[PMID: 10397494]
NCI-H460	IC₅₀	60 μM Compound: 1	Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay Inhibition of human NCI-H460 cell proliferation by sulphorodhamine B assay	[PMID: 19595598]
NIH3T3	IC₅₀	> 1000 μM Compound: 1	Inhibition of mouse NIH/3T3 cell proliferation by MTT assay Inhibition of mouse NIH/3T3 cell proliferation by MTT assay	[PMID: 19595598]
NIH3T3	IC₅₀	> 200 μM Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by SRB assay	[PMID: 23711920]
NIH3T3	IC₅₀	305.77 μg/mL Compound: Ciprofloxacin	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay	[PMID: 28174104]
Osteoblast	IC₅₀	> 400 μg/mL Compound: Ciprofloxacin	Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs	[PMID: 17088489]
Osteoblast	IC₅₀	170 μg/mL Compound: Ciprofloxacin	Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs	[PMID: 17088489]
PBMC	IC₅₀	> 0.5 mM Compound: CPX, B-H	Cytotoxicity against human PBMC measured after overnight incubation by MTT assay Cytotoxicity against human PBMC measured after overnight incubation by MTT assay	[PMID: 21855181]
PC-3	IC₅₀	101.4 μM Compound: CP	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
PC-3	IC₅₀	143 μM Compound: 1	Antitumor activity against human PC3 cells after 5 days by MTT assay Antitumor activity against human PC3 cells after 5 days by MTT assay	[PMID: 19595598]
SH-SY5Y	IC₅₀	> 0.5 mM Compound: CPX, B-H	Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay Cytotoxicity against human SH-SY5Y cells measured after overnight incubation by MTT assay	[PMID: 21855181]
SK-MEL	IC₅₀	196 μM Compound: 1	Inhibition of human SK-MEL cell proliferation by MTT assay Inhibition of human SK-MEL cell proliferation by MTT assay	[PMID: 19595598]
SK-MEL3	IC₅₀	> 128 μM Compound: CFX	Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SK-MEL3	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SK-MEL-3 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	≥ 100 μM Compound: Ciprofloxacin	Antiproliferative activity against human SMMC7721 cells by MTT assay Antiproliferative activity against human SMMC7721 cells by MTT assay	[PMID: 30660827]
SMMC-7721	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
Splenocyte	IC₅₀	> 40 μM Compound: CIPRO	Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method Cytotoxicity against concanavalin-stimulated BALB/c mouse splenocytes after 72 hrs by resazurin dye reduction method	[PMID: 19908867]
SW480	IC₅₀	> 128 μM Compound: CFX	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31881454]
SW480	IC₅₀	128 μM Compound: 1	Inhibition of human SW480 cell proliferation by MTT assay Inhibition of human SW480 cell proliferation by MTT assay	[PMID: 19595598]
SW480	IC₅₀	137 μM Compound: Ciprofloxacin	Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SW480 cells assessed as reduction in cell viability by MTT assay	[PMID: 30660827]
SW480	IC₅₀	160.4 μM Compound: CP	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
SW-620	IC₅₀	200.4 μM Compound: CP	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31678743]
THP-1	IC₅₀	60.5 μM Compound: Ciprofloxacin	Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 24650715]
U-373MG ATCC	IC₅₀	96 μM Compound: 1	Antitumor activity against human U373MG cells after 5 days by MTT assay Antitumor activity against human U373MG cells after 5 days by MTT assay	[PMID: 19595598]
V79	IC₅₀	> 1000 μM Compound: 1	Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA Inhibition of chinese hamster V79 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA	[PMID: 19595598]
Vero	IC₅₀	> 188.5 μM Compound: Ciprofloxacin	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	[PMID: 19131245]
Vero	CC₅₀	128 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30025351]
Vero	CC₅₀	512 μg/mL Compound: CPFX	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30690301]
Vero	CC₅₀	600.8 μM Compound: CPFX	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assat	[PMID: 21146257]
WI-38	IC₅₀	> 100 μM Compound: Ciprofloxacin	Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay Antiproliferative activity against human WI38 cells after 24 hrs by BrdU incorporation assay	[PMID: 27555286]

In Vitro

Ciprofloxacin (Bay-09867) monohydrochloride (5-50 μg/mL; 0-24 h; tendon cells) inhibits cell proliferation and causes cell cycle arrest at the G2/M phase^[1].
? Ciprofloxacin (Bay-09867) monohydrochloride shows potent activity against Y. pestis and B. anthracis with MIC₉₀ of 0.03 μg/mL and 0.12 μg/mL, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	Tendon cells
Concentration:	5, 10, 20 and 50 μg/mL
Incubation Time:	24 hours
Result:	Decreased the cellularity of tendon cells.

Cell Cycle Analysis^[1]

Cell Line:	Tendon cells
Concentration:	50 μg/mL
Incubation Time:	24 hours
Result:	Arrested cell cycle at the G2/M phase and inhibited cell division in tendon cells.

Western Blot Analysis^[1]

Cell Line:	Tendon cells
Concentration:	50 μg/mL
Incubation Time:	0, 6, 12, 17 and 24 hours
Result:	Down-regulated the expression of CDK-1 and cyclin B protein and mRNA. Up-regulated the expression of PLK-1 protein.

In Vivo

Ciprofloxacin (Bay-09867) monohydrochloride (30 mg/kg; i.p.; for 24 hours; BALB/c mice) has protection against Y. pestis in murine model of pneumonic plague^[3].
? Ciprofloxacin (Bay-09867) monohydrochloride (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture by decreases LOX level and increases MMP levels and activity in the aortic wall^[4].
? Ciprofloxacin (Bay-09867) monohydrochloride (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) induces DNA damage and release of DNA to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling. Ciprofloxacin lactate increases apoptosis and necroptosis in the aortic wall^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice^[3]
Dosage:	30 mg/kg
Administration:	Intraperitoneal injection; for 24 hours
Result:	Reduced the lung bacterial load in murine model of pneumonic plague.

Animal Model:	C57BL/6J mice^[4]
Dosage:	100 mg/kg
Administration:	Oral gavage; daily, for 4 weeks
Result:	Had aortic destruction that was accompanied by decreased LOX expression and increased MMP expression and activity.

Animal Model:	C57BL/6J mice^[4]
Dosage:	100 mg/kg
Administration:	Oral gavage; daily, for 4 weeks
Result:	Caused mitochondrial DNA and nuclear DNA damage, leading to mitochondrial dysfunction and ROS production. Increased apoptosis and necroptosis in the aortic wall.

Clinical Trial

Molecular Weight

367.80

Formula

C₁₇H₁₉ClFN₃O₃

CAS No.

93107-08-5

Appearance

Solid

Color

White to off-white

SMILES

[H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility

In Vitro:

H₂O : 12.5 mg/mL (33.99 mM; Need ultrasonic)

DMSO : 5 mg/mL (13.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7189 mL	13.5943 mL	27.1887 mL
5 mM	0.5438 mL	2.7189 mL	5.4377 mL
10 mM	0.2719 mL	1.3594 mL	2.7189 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 0.5 mg/mL (1.36 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 0.5 mg/mL (1.36 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 100%

Select Batch:

Data Sheet (281 KB) SDS (394 KB)

COA (249 KB) HNMR (230 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Tsai WC, et, al. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008 Jun;58(6):1657-63. [Content Brief]

[2]. Steenbergen J, et, al. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02434-16. [Content Brief]

[3]. Hamblin KA, et, al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.

[4]. LeMaire SA, et, al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018 Sep 1;153(9):e181804. [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / H₂O	1 mM	2.7189 mL	13.5943 mL	27.1887 mL	67.9717 mL
	5 mM	0.5438 mL	2.7189 mL	5.4377 mL	13.5943 mL
	10 mM	0.2719 mL	1.3594 mL	2.7189 mL	6.7972 mL
H₂O	15 mM	0.1813 mL	0.9063 mL	1.8126 mL	4.5314 mL
	20 mM	0.1359 mL	0.6797 mL	1.3594 mL	3.3986 mL
	25 mM	0.1088 mL	0.5438 mL	1.0875 mL	2.7189 mL
	30 mM	0.0906 mL	0.4531 mL	0.9063 mL	2.2657 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Ciprofloxacin monohydrochloride Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ciprofloxacin monohydrochloride93107-08-5Bay-09867 monohydrochlorideTopoisomeraseApoptosisAntibioticBacterialMitochondrial MetabolismReactive Oxygen SpeciesmitochondrialDNADNA damageanti-proliferativeantibioticROSInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ciprofloxacin monohydrochloride (Synonyms: Bay-09867 monohydrochloride)

Customer Review

Other Forms of Ciprofloxacin monohydrochloride:

Ciprofloxacin monohydrochloride Related Antibodies

29 Publications Citing Use of MCE Ciprofloxacin monohydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Ciprofloxacin monohydrochloride Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ciprofloxacin monohydrochloride Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report